Last week, Irish drug maker Allergan announced that it had transferred its patents for its cyclosporine ophthalmic emulsion, Restasis, to the Saint Regis Mohawk Tribe. Allergan said in a statement that the Tribe now owns all Orange Book-listed patents for the dry eye treatment, and that the Tribe is filing for a motion to dismiss an ongoing inter partes review on the basis of sovereign immunity.
Last week, Irish drug maker Allergan announced that it had transferred its patents for its cyclosporine ophthalmic emulsion, Restasis, to the Saint Regis Mohawk Tribe. Allergan said in a statement that the Tribe now owns all Orange Book-listed patents for the dry eye treatment, and that the Tribe is filing for a motion to dismiss an ongoing inter partes review (IPR) on the basis of sovereign immunity.
Under the agreement, the Tribe will receive $13.75 million from Allergan when the agreement is executed, and an additional $15 million per year in royalties on sales of the drug. According to the Mohawk Tribal Council, “This is a viable and sound opportunity for the Saint Regis Mohawk Tribe to enter into the patent, technology and research sector as part of our overall economic diversification strategy.”
A spokesperson for Teva Pharmaceuticals, which is one of the companies challenging Allergan’s patents on Restasis, told The New York Times that Teva “will be interested to see what comments are made about this tactic by regulatory agencies.”
The rest of the pharmaceutical industry, taken by surprise by Allergan’s strategy, will likely also look with interest on how the United States will address this unusual tactic to block generic drug makers from creating competing versions of its product. Pharma may also look to Allergan’s example as a model for how to transfer their patents to sovereign entities in exchange for regular royalties.
While Allergan’s latest tactic may be novel, reference product sponsors have used other approaches to delay generic and biosimilar competition for some time. Among practices that have been called into question are the following:
Restricted distribution. In order for a generic or biosimilar maker to develop a product, the company will require access to samples of the originator product. Some drug makers, critics allege, inappropriately restrict competitors’ access to samples by implementing safety programs that restrict distribution of samples.
Product-hopping. This practice involves making slight alterations that hold no significant therapeutic value to an existing drug and patenting the resulting product as though it were a new drug. Changes to drugs under a product-hopping strategy might include a change of form from a short-acting capsule to an extended-release tablet.
Pay-for-delay agreements. In recent testimony to the House Judiciary Committee, FDA Commissioner, Scott Gottlieb, MD, described pay-for-delay agreements as settlements in which drug companies resolve patent disputes by agreeing with generic drug makers to delay competitive products’ entry in exchange for payment. Gottlieb stopped short of saying that approach stymied competition, saying “we do not know when generic products would have entered the market if the patent litigation had continued and the companies had not settled with an agreement to delay marketing.”
Delivery device changes. According to Stat News, complex generics like Mylan’s EpiPen, an epinephrine product, which was recently the subject of controversy when its price suddenly spiked, can attain “virtual immortality” when they make adjustments to delivery devices. Mylan’s patent-protected change to the EpiPen’s push-button injector device effectively allowed it to stave off competition.
Extensive patenting. AbbVie has protected its reference adalimumab, Humira, with what Goodwin attorney Robert Cerwinski, JD, has called “a veritable patent thicket.” While the majority of patent protection for Humira has already expired, AbbVie has secured additional patents to the product that biosimilar developers must litigate either in IPR proceedings or under the Biologics Price Competition and Innovation Act pathways, both of which can be lengthy and costly.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.